Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445222 | 0.81 | HRH3 (0.44) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 | |
| SCHEMBL6444126 | 0.81 | DRD2 (0.47) | EPHX1EPHX2 | |
| SCHEMBL22793920 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 | |
| SCHEMBL178287 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 | |
| SCHEMBL31273888 | 0.79 | HRH3 (0.49) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL27414943 | 0.78 | GNAO1 (0.49) | HRH3EPHX1EPHX2 | |
| Fluoride SCHEMBL29252276 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 | |
| SCHEMBL22520700 | 0.75 | ACHE (0.50) | SMN1; SMN2HRH3HSD11B1ALDH1A1 | |
| SCHEMBL2439300 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 | |
| SCHEMBL21532979 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HRH3EPHX1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641908-B | Five-membered heterocyclic [3,4-d ] pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-11-19 | — | — | CN | disclosed |
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3470415-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-04-17 | — | — | EP | disclosed |
| CN-109641908-A | Five-ring heterocycles simultaneously [3,4-d] pyridazinone compound, preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2019-04-16 | — | — | CN | disclosed |
| CN-107417687-A | Five-ring heterocycles simultaneously [3,4 d] pyridazinone compound, its preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2017-12-01 | — | — | CN | disclosed |
| US-6858679-B2 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030153693-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | QUIRK RODERIC PAUL (US) | 2003-08-14 | — | — | US | disclosed |
| US-6605564-B1 | Anionic polymerization initiators and salt additives selected from sodium chloride, sodium iodide, potassium chloride, potassium t-butoxide, for increasing the efficiency of reactions between living polymer anions and electrophiles | FMC CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-6545103-B2 | Living polymers | FMC CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020010082-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6184338-B1 | USEFUL IN THE PREPARATION OF TERTIARY AMINE CONTAINING POLYMERS, INCLUDING LINEAR, HOMOTELECHELIC, HETEROTELECHELIC AND RADIAL POLYMERS. | FMC CORPORATION | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | FGFR1, FGFR3, FGFR4 | SMN1; SMN2 2313/4885HRH3 1614/4885EPHX1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.